Biopharma’s optimism rises 13%, yet falls short of 2022 peak, reports GlobalData

New Delhi: The biopharmaceutical industry is experiencing a resurgence in optimism regarding its growth prospects for the next year, according to a recent survey by GlobalData.

The survey reveals a significant 13% increase in confidence over the past six months, yet despite this positive trend, overall confidence levels have not yet reached those seen in 2022.

GlobalData’s mid-year update of “The State of the Biopharmaceutical Industry 2024” survey reveals that 73% of healthcare industry professionals feel optimistic or very optimistic about the industry’s growth in the coming 12 months. This represents a significant increase from six months ago when only 60% expressed such sentiment, and a further rise from 47% in 2023. Nevertheless, this year’s optimism still lags behind the high of 81% recorded in 2022.

Urte Jakimaviciute, Senior Director of Market Research and Thematic Intelligence at GlobalData, stated, “Despite the ongoing challenges in the geopolitical landscape, there is a gradual decline in inflation, which provides a more stable environment for biotech funding to show signs of recovery, signalling renewed confidence. Supply chain disruptions that plagued the pharmaceutical industry during the past few years are becoming less intense. This gives hope that the industry is on the path of rebounding from the impact of the COVID-19 pandemic and subsequent geopolitical conflicts. “

However, the survey also highlights persistent concerns that could hinder growth. Industry professionals identified geopolitical conflicts and drug pricing and reimbursement pressures as the main obstacles for the pharmaceutical sector over the next year.

“Geopolitical conflicts and tensions have become potent disruptors casting uncertainty over international relations, investment, and supply chains,” Jakimaviciute noted. “Pricing and reimbursement pressures have a direct impact on pharma’s profitability and investments. For example, the Inflation Reduction Act (IRA) that aims to reduce drug prices in the US, introduced government price negotiation for selected pharmaceuticals, with companies refusing to participate in pricing negotiations facing steep penalties.”

“While the current respondents’ sentiment is promising and indicative of potential growth, geopolitical uncertainties coupled with drug pricing and reimbursement pressures remain influential factors that may impact investment confidence and growth prospects.”

The survey, conducted globally from April 4 to May 10, 2024, gathered responses from 124 healthcare industry professionals. Despite the challenges, the overall trend indicates a sector gradually regaining its footing after years of disruption.